1. Home
  2. CAVA vs EXAS Comparison

CAVA vs EXAS Comparison

Compare CAVA & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CAVA Group Inc.

CAVA

CAVA Group Inc.

HOLD

Current Price

$53.71

Market Cap

6.2B

ML Signal

HOLD

Logo Exact Sciences Corporation

EXAS

Exact Sciences Corporation

HOLD

Current Price

$101.58

Market Cap

11.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAVA
EXAS
Founded
2006
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.2B
11.0B
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
CAVA
EXAS
Price
$53.71
$101.58
Analyst Decision
Buy
Buy
Analyst Count
19
20
Target Price
$78.84
$77.94
AVG Volume (30 Days)
4.1M
10.8M
Earning Date
11-04-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
151.16
N/A
EPS
1.16
N/A
Revenue
$1,132,074,000.00
$3,082,033,000.00
Revenue This Year
$23.90
$19.40
Revenue Next Year
$20.52
$13.51
P/E Ratio
$45.84
N/A
Revenue Growth
23.93
14.47
52 Week Low
$43.41
$38.81
52 Week High
$144.49
$101.95

Technical Indicators

Market Signals
Indicator
CAVA
EXAS
Relative Strength Index (RSI) 52.15 89.65
Support Level $51.21 $100.95
Resistance Level $55.87 $101.95
Average True Range (ATR) 2.18 0.35
MACD 0.79 -0.87
Stochastic Oscillator 70.55 61.17

Price Performance

Historical Comparison
CAVA
EXAS

About CAVA CAVA Group Inc.

Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates all of its revenue from the CAVA segment.

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Share on Social Networks: